Arbutus Biopharma Corporation ABUS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $160.72M+310% | -$33.5M+52.1% | -$42.28M+44.9% | -$54.25M+29.6% | -$76.57M-2.9% | ||
| $44K-96.8% | $363K-73.7% | $685K-51.3% | $1.01M-29.8% | $1.36M-4.9% | ||
| $4.75M-54.9% | $6.95M-22.6% | $7.32M-19.3% | $8.22M-12.6% | $10.54M+14.7% | ||
| -$34.36M+41.7% | -$39.64M+38.9% | -$45.27M+37.0% | -$60.19M+17.4% | -$58.95M+24.4% | ||
| —— | —— | —— | —— | —— | ||
| $14.56M-52.0% | $5.72M-89.0% | $5.5M-89.9% | $6.43M-88.2% | $30.35M-12.4% | ||
| -$13.37M— | -$18.32M— | -$9.44M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arbutus Biopharma Corporation generate?
- Arbutus Biopharma Corporation (ABUS) generated -$34.4M in operating cash flow over the trailing twelve months.
- Where does Arbutus Biopharma Corporation's cash flow data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
